Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Clinical Trial of Tamibarotene in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT06289998 is registered in ClinicalTrials.gov with Rege Nephro Co., Ltd. as lead sponsor.

NCT NCT06289998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06289998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Clinical Trial of Tamibarotene in Patients With Autosomal Dominant Polycystic Kidney Disease
Lead sponsor
Rege Nephro Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 22, 2023
Completion date
December 31, 2025
Enrollment
70 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant polycystic kidney disease (adpkd)